Abstract:Abstract 4815 Introduction: Acute myeloid leukemia (AML) is the most common type of adult leukemia for which cytosine arabinoside(Ara-C)-based chemotherapy is the main treatment. However, there is a significant difference in treatment response and survival, especially among large groups of patients with the same disease classification. Single nucleotide polymorphisms within the nucleotide excision repair pathway may alter the susceptibility of leukemia cells to chemotherapy. We investigated the role of six single nucleotide polymorphisms (ERCC5rs76871136, ERCC5rs77569659, ERCC5rs873601, XPCrs2228000, XPCrs2228001, and XPCrs1870134) within the nucleotide excision repair pathway on the outcome of patients with AML treated with cytosine arabinoside-based chemotherapy. Methods: One hundred fifty-one patients with AML in a Chinese population were enrolled in this study. Patients diagnosed with other cancers or other hematological malignancies were excluded in this study. This study was approved by the ethics committee of Southeast University in compliance with Chinese guidelines for blood donation, and informed consent for genetic analysis was obtained from all participants according to the Declaration of Helsinki. All patients received Ara-C-based standard induction chemotherapy regimens. Patients were divided into three groups, according to cytogenetic risk. Moreover, the evaluation standard of these patients were evaluated by age(£40 years, 40–60 years, and 360 years), WBC (>50 ′ 109/L vs. £50 ′ 109/L), hemoglobin level (>100 g/L vs. £100 g/L), and platelet count (>60 ′ 109/L vs. £60 ′ 109/L). Genotypes were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Deviations from the Hardy–Weinberg equilibrium for genotypes and haplotype frequencies as well as haplotype–trait associations were assessed with Pearson's c2 analysis using SHEsis. Once the expected number in any cell was less than five, demographic and clinical data across genotypes were compared using Pearson's c2analysis or Fisher's exact test. Significant genotypic differences among the different responders were calculated using Pearson's c2analysis. P <0.05 was considered statistically significant. We estimated the relative risk of responding to treatment with the genotypes as odds ratio(OR) and 95% confidence intervals(95%CI) using conditional logistic regression with adjustment for the effects of covariates. All statistical tests were two-sided and performed using SPSS 17.0. Results: Genotype frequencies for the polymorphisms were found to be in Hardy–Weinberg equilibrium. The results indicated that the distribution of three genotypes of XPCrs1870134 significantly differed among the cytogenetic risk groups (P = 0.04). The frequency of the CC genotype of XPCrs2228001 was significantly higher in male patients than in female patients (P = 0.03), whereas that of the CC genotype of XPCrs2228000 was significantly higher in patients with a hemoglobin level of 100 g/L or less compared with those who had a hemoglobin level greater than 100 g/L (P = 0.039).Moreover, patients carrying at least one variant allele (XPCrs2228001AA+CC) were more likely to respond better than those who did not carry a variant. However, no significant association was detected between polymorphisms in ERCC5 and treatment response. Conclusions: These findings suggest that XPC polymorphisms are important markers for the outcome of patients with AML in the Chinese population. Disclosures: No relevant conflicts of interest to declare.

Genetic Variations Of Dna Repair Genes And Their Prognostic Significance In Patients With Acute Myeloid Leukemia

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Genetic variations in DNA excision repair pathway contribute to the chemosensitivity and prognosis of acute myeloid leukemia

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

[Polymorphisms of RAD51(G135C) and XRCC3(C241T) Genes and Correlations Thereof with Prognosis and Clinical Outcomes of Acute Myeloid Leukemia].

Polymorphisms in XPC Provide Prognostic Information in Acute Myeloid Leukemia

Polymorphisms in XRCC5, XRCC6, XRCC7 Genes Are Involved in DNA Double-Strand Breaks(dsbs) Repair Associated with the Risk of Acute Myeloid Leukemia(aml) in Chinese Population

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Genetic Polymorphisms and Treatment Response in Advanced Non-Small Cell Lung Cancer.

ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS

Genetic variants of nucleotide excision repair pathway and outcomes of induction therapy in acute myeloid leukemia

Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.

Immune checkpoint‐related gene polymorphisms are associated with acute myeloid leukemia

Mitochondrial apoptosis-related gene polymorphisms are associated with responses to anthracycline-based chemotherapy in acute myeloid leukaemia

Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML)

[Relationship Between RAD51-g135C and XRCC3-C241T Polymorphisms and Prognosis of Inv (16)/ T(16;16) (Cbfbeta-Myh11) Acute Myeloid Leukemia].

RAD51 and XRCC3 Polymorphisms: Impact on the Risk and Treatment Outcomes of De Novo Inv(16) or T(16;16)/cbfβ–myh11(+) Acute Myeloid Leukemia

Risk of MDM2 SNP309 Alone or in Combination with the P53 Codon 72 Polymorphism in Acute Myeloid Leukemia.

The Association of Genetic Variations in DNA Repair Pathways with Severe Toxicities in NSCLC Patients Undergoing Platinum-Based Chemotherapy.

Genetic Variants in DNA Mismatch Repair Pathway predict prognosis of Lung Cancer patients with receiving Platinum-Based Chemotherapy.